Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Exelixis Inc. | Zanzalintinib - (STELLAR-304) | Advanced non-clear cell renal cell carcinoma (nccRCC) | Phase 3 | Ongoing | Oral | Oncology |
| Exelixis Inc. | Zanzalintinib - (STELLAR-304) | Advanced non-clear cell renal cell carcinoma (nccRCC) | Phase 3 | Ongoing | Oral | Oncology |
| Exelixis Inc. | XL092 with atezolizumab - (STELLAR-303) | Colorectal Cancer (CRC) | PDUFA | Data Released | Intravenous | Oncology |
| Exelixis Inc. | Zanzalintinib and WELIREG (belzutifan) - (LITESPARK-033) | First-line advanced RCC | Phase 3 | Ongoing | Oral | Oncology |
| Exelixis Inc. | CABOMETYX (cabozantinib) and TECENTRIQ (atezolizumab) - (CONTACT-02) | Castration-Resistant Prostate Cancer | sNDA Filing | Data Released | Oral and intravenous | Oncology |
| Exicure Inc. | burixafor (GPC-100/TG-0054) in combination with granulocyte colony-stimulating factor (G-CSF) | Multiple myeloma (MM) | Phase 2 | Ongoing | Subcutaneous | Oncology |
| Exicure Inc. | GPC-100 (burixafor) in combination with propranolol and G-CSF | Multiple myeloma (MM) | Phase 2 | Data Released | oral | Oncology |
| EyePoint Inc. | DURAVYU ( EYP-1901 vorolanib intravitreal) - (PAVIA) | Non-proliferative diabetic retinopathy (NPDR) | Phase 2 | Data Released | Intravitreal | Opthalmic |
